Prof Del Aguila

FDA Recommends Against the Continued Use of Meridia (sibutramine) Safety Announcement Additional Information for Patients Additional Information for Healthcare Professionals Data Summary Safety Announcement [10-8-2010] The U.S. Food and Drug Administration (FDA) is recommending against continued prescribing and use of Meridia (sibutramine) because this drug may pose unnecessary cardiovascular risks to patients. FDA has requested that Abbott Laboratories—the manufacturer of Meridia—voluntarily withdraw this drug product from the United States market. Abbott has agreed to voluntarily stop marketing of Meridia in the United States. Meridia was FDA-approved in November 1997 for weight loss and maintenance of weight loss in patients with a body mass index (BMI) greater than or equal to 30 (≥30) kg/m2 or for patients with a BMI ≥27 kg/m2 who have other cardiovascular risk factors. BMI is a measure of body fat in adults that is based on height and weight. Patients with a BMI ≥30 kg/m2 are c

Bienvenidos a mi página de Endocrinología y Nutrición pediátrica

Endocrinologia!!! View more presentations from steffysolecita2010 .

An Fac med. 2010;71(1):13-7 Resistencia a insulina en adolescentes obesos Insulin resistance in obese adolescents Maria Isabel Rojas-Gabulli1,2, Oswaldo Núñez1,2, Carlos Del Águila1,2, Mariel Briceño1, Nelly Valenzuela2 1 Servicio de Endocrinología, Instituto Nacional de Salud del Niño. Lima, Perú. 2 Facultad de Medicina, Universidad Nacional Federico Villarreal. Lima, Perú. Resumen Introducción: La obesidad en niños y adolescentes es un problema de salud pública que se encuentra en incremento a nivel mundial, siendo conocida su relación con el desarrollo de alteraciones metabólicas como la diabetes mellitus tipo 2. Objetivos: Determinar la presencia de resistencia a la insulina en adolescentes obesos y no obesos según sexo, edad, estadio puberal y antecedentes familiares de alteración metabólica o enfermedad cardiovascular (ECV) explorando asociación y riesgo. Diseño: Estudio transversal, observacional y analítico. Lugar: Tres centros educativos de la zona urbana de Lima. Participante

La Endocrinologia Pediátrica estudia las alteraciones hormonales, metabolicas y problemas del crecimiento y desarrollo del Niño

Current Status of Islet Cell Replacement and Regeneration Therapy Philippe A. Halban, Michael S. German, Steven E. Kahn, and Gordon C. Weir Department of Genetic Medicine and Development (P.A.H.), University of Geneva, 1211 Geneva 4, Switzerland; Hormone Research Institute (M.S.G.), Diabetes Center, University of California, San Francisco, San Francisco, California 94143-0534; Department of Medicine (S.E.K.), Division of Metabolism, Endocrinology, and Nutrition, Veterans Affairs Puget Sound Health Care System and University of Washington, Seattle, Washington 98195; and Section of Islet Transplantation and Cell Biology (G.C.W.), Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts 02215 Context: cell mass and function are decreased to varying degrees in both type 1 and type 2 diabetes. In the future, islet cell replacement or regeneration therapy may thus offer therapeutic benefit to people with diabetes, but there are major challenges to be overcome. Evidence Acquisi

March 31, 2010 Joint Statement on Radioactive Precautions Following Radioactive Iodine Therapy The American Thyroid Association (ATA), The Endocrine Society (TES), the Society of Nuclear Medicine (SNM), the American Association of Clinical Endocrinologists (AACE) Radioactive iodine (I-131) has been used for decades as an effective treatment for thyroid cancer. Throughout this time, one important aspect of such treatment has been the protection of the public, and more specifically household contacts, from theoretically dangerous exposure to residual radiation remaining in the patient’s body after treatment. The Nuclear Regulatory Commission (NRC), an agency of the Federal government, sets the rules governing this aspect of I-131 treatment and revises them periodically 1 . In 1997, the NRC modified these regulations to allow individualization of the procedure for preventing radiation exposure to the public after a patient is treated with I-131. A goal of this rule change

Medline®Citation Metabolic alterations during valproic acid treatment: a prospective study. Abaci A, Saygi M, Yis U, Demir K, Dirik E, Bober E Pediatric neurology 200912 41(6):435-9 Language: eng Country: United States Division of Endocrinology, Department of Pediatrics, Faculty of Medicine, Dokuz Eylül University, Izmir, Turkey. We prospectively examined the effects of valproic acid on the endocrine system and metabolic variables in epileptic children. Patients with newly diagnosed idiopathic epilepsy were included in the study. Laboratory and clinical variables were assessed before and after 6 and 12 months of treatment. In total, 30 patients (mean

COMUNICACIÓN SOBRE RIESGOS DE MEDICAMENTOS PARA PROFESIONALES SANITARIOS Ref: 2010/01 21 de enero de 2010 NOTA INFORMATIVA SIBUTRAMINA (REDUCTIL®): SUSPENSIÓN CAUTELAR DE COMERCIALIZACIÓN Como continuación de la nota informativa 2009/13 , la Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) comunica a los profesionales sanitarios que se ha tomado la decisión de suspender la comercialización de sibutramina, disponible en España con el nombre comercial Reductil® . Tras la revisión de los resultados preliminares del estudio SCOUT (Sibutramine Cardiovascular OUTcome trial) y los datos disponibles sobre la eficacia de sibutramina, el Comité de Medicamentos de Uso Humano

http://www.lapaginadelmedico.com.ar/BALANCE%20HIDROSALINO.pdf

International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes THE INTERNATIONAL EXPERT COMMITTEE* An International Expert Committee with members appointed by the American Diabetes Association, the European Association for the Study of Diabetes, and the International Diabetes Federation was convened in 2008 to consider the current and future means of diagnosing diabetes in nonpregnant individuals. The report of the International Expert Committee represents the consensus view of its members and not necessarily the view of the organizations that appointed them. The International Expert Committee hopes that its report will serve as a stimulus to the international community and professional organizations to consider the use of the A1C assay for the diagnosis of diabetes. Diabetes is a disease characterized by abnormal metabolism, most notably hyperglycemia, and an associated heightened risk for relatively specific long-term complications affecting the eyes,